Short answer
Greenwich LifeSciences, Inc. (GLSI) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$4M
- −55.6% YoY · −3.1% QoQ
- EPS (diluted)
- −$0.30
- −42.9% YoY · +0.0% QoQ
Source: XBRL data from the Greenwich LifeSciences, Inc. (GLSI) Q3 2025 10-Q on SEC EDGAR. USD.
Greenwich LifeSciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; clinical-stage company without commercialization
- R&D expenses $3.52M, up 54% YoY from $2.29M
- G&A expenses $653,066, up 49% YoY from $437,011
- Cash $3.81M vs $4.09M at December 31, 2024; operating cash use $6.74M vs $5.41M
- Additional capital required; ongoing losses, clinical expenses, and equity-financing needs as headwinds
Risk Factors
- No newly added risk factor; filing reports no material changes from the December 31, 2024 Form 10-K
- No materially updated risk identified; prior-year risk disclosures remain unchanged
- No new regulatory, legal, or compliance risk disclosed this quarter
- No new operational, competitive, market, liquidity, debt, currency, or concentration risk disclosed this quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Greenwich LifeSciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.